Fecal microbiota transplantation in the management of hepatic encephalopathy
Dina Kao, Brandi Roach, Heekuk Park, Naomi Hotte, Karen Madsen, Vince Bain, Puneeta Tandon – 11 August 2015
Fecal microbiota transplantation in the management of hepatic encephalopathy
Dina Kao, Brandi Roach, Heekuk Park, Naomi Hotte, Karen Madsen, Vince Bain, Puneeta Tandon – 11 August 2015
Research is needed on the difficult‐to‐cure population of hepatitis C virus patients with disability
Viktor Chirikov, Fadia Shaya, C. Daniel Mullins, Susan dosReis, Eberechukwu Onukwugha, Charles Howell – 11 August 2015
Impact of body mass index on posttransplant outcomes reexamined
Khurram Bari, Pratima Sharma – 11 August 2015
Once‐daily prolonged release tacrolimus in liver transplantation: Experts' literature review and recommendations
Audrey Coilly, Yvon Calmus, Faiza Chermak, Jerome Dumortier, Christophe Duvoux, Olivier Guillaud, Pauline Houssel‐Debry, Martine Neau‐Cransac, Jeanick Stocco – 11 August 2015 – The efficacy and safety of tacrolimus (Tac) twice daily (bid) and once a day (qd) formulations are considered to be similar. However, the available information regarding initiation of Tac qd is sparse, and practical information is lacking.
Natural killer cells regulate T cell immune responses in primary biliary cirrhosis
Shinji Shimoda, Satomi Hisamoto, Kenichi Harada, Sho Iwasaka, Yong Chong, Minoru Nakamura, Yuki Bekki, Tomoharu Yoshizumi, Ken Shirabe, Toru Ikegami, Yoshihiko Maehara, Xiao‐Song He, M. Eric Gershwin, Koichi Akashi – 11 August 2015 – The hallmark of primary biliary cirrhosis (PBC) is the presence of autoreactive T‐ and B‐cell responses that target biliary epithelial cells (BECs). Biliary cell cytotoxicity is dependent upon initiation of innate immune responses followed by chronic adaptive, as well as bystander, mechanisms.
Diabetes and prediabetes in patients with hepatitis B residing in North America
Mandana Khalili, Manuel Lombardero, Raymond T. Chung, Norah A. Terrault, Marc G. Ghany, W. Ray Kim, Daryl Lau, Mauricio Lisker‐Melman, Arun Sanyal, Anna S. Lok, for the HBRN – 8 August 2015 – Diabetes is associated with liver disease progression and increased hepatocellular carcinoma risk, but factors associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North America are unknown. We aimed to determine factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV‐infected multiethnic cohort.
Diabetes and prediabetes in patients with hepatitis B residing in North America
Mandana Khalili, Manuel Lombardero, Raymond T. Chung, Norah A. Terrault, Marc G. Ghany, W. Ray Kim, Daryl Lau, Mauricio Lisker‐Melman, Arun Sanyal, Anna S. Lok, for the HBRN – 8 August 2015 – Diabetes is associated with liver disease progression and increased hepatocellular carcinoma risk, but factors associated with diabetes in patients with chronic hepatitis B virus (HBV) infection in North America are unknown. We aimed to determine factors predictive of diabetes and impaired fasting glucose (IFG) in a large HBV‐infected multiethnic cohort.
Hepatoma in hepatitis B: Infectious disease or liver disease?
David K. Wong – 7 August 2015
High‐throughput T‐cell receptor sequencing across chronic liver diseases reveals distinct disease‐associated repertoires
Evaggelia Liaskou, Eva Kristine Klemsdal Henriksen, Kristian Holm, Fatemeh Kaveh, David Hamm, Janine Fear, Marte K. Viken, Johannes Roksund Hov, Espen Melum, Harlan Robins, Johanna Olweus, Tom H. Karlsen, Gideon M. Hirschfield – 7 August 2015 – Hepatic T‐cell infiltrates and a strong genetic human leukocyte antigen association represent characteristic features of various immune‐mediated liver diseases. Conceptually the presence of disease‐associated antigens is predicted to be reflected in T‐cell receptor (TCR) repertoires.